How to Buy Astrazeneca Pharma India Share?

You can easily buy Astrazeneca Pharma India shares in Groww by creating a demat account and getting the KYC documents verified online.

What is the Market Cap of Astrazeneca Pharma India?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Astrazeneca Pharma India is ₹22,272 Cr as of 28 Dec ‘25.

What is the PE and PB ratio of Astrazeneca Pharma India?

The PE and PB ratios of Astrazeneca Pharma India is 111.83 and 27.87 as of 28 Dec ‘25

What is the 52 Week High and Low of Astrazeneca Pharma India?

The 52-week high/low is the highest and lowest price at which a Astrazeneca Pharma India stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Astrazeneca Pharma India is ₹6,312.75 and ₹10,691.00 as of 28 Dec ‘25

Stocks

Invest in Stocks

Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.

Intraday

Monitor top intraday performers in real time

ETF Screener

Get the best of Mutual Funds and flexibility of Stocks

IPO

Track upcoming and ongoing IPOs

MTFs

Buy now, pay later

Stock Screener

Filter based on RSI, PE ratio and more

Stock Events

Dividends, bonus, buybacks and more

Demat Account

Begin your stock market journey

Share Market Today

Live news updates from stock market

F&O

Trade in Futures & Options

Trade in F&O using the terminal. View charts, indicators, track your orders , P&L and watchlists in a single space

Indices

Track markets across the globe

Terminal

Track charts, orders, positions, watchlists in one place

Option chain

Analyse chains, view payoffs, create baskets

Pledge

Get extra balance for trading

Commodities

Trade in Crude Oil, Gold, Silver and more

API trading

Set up and execute trades through our API

Mutual Funds

Invest in Mutual Funds

Invest in direct mutual funds at zero charges via lump sump investments or SIPs

Mutual Fund Houses

Know about AMCs, funds, fund managers

NFO’s

Track all active NFOs in one place

Mutual Funds by Groww

Mutual funds by Groww designed for your investment goals

Start SIP

Build long-term wealth through disciplined monthly investing.

Mutual Funds screener

Filter funds based on risk, fund size and more

Track Funds

Import funds and track all investments in a single place

Compare Funds

SIP calculator

Estimate returns on a SIP

Brokerage calculator

Estimate charges for your trade/investment

Margin calculator

Estimate balance needed to buy/sell a stock

SWP calculator

Returns on your systematic withdrawal plan

Pricing

Brokerage and charges on Groww

Blog

Create Alert

Watchlist

Astrazeneca Pharma India

₹9,039.00

+160.00 (1.80%) 1D

NSE

All

Terminal

Create Stock SIPAutomate your investments in this

Performance

Open
8,977.00
Prev. Close
8,879.00
Volume
4,855
Total traded value
4.39 Cr
Upper Circuit
10,654.50
Lower Circuit
7,103.50

Fundamentals

Market Cap	₹22,272Cr
ROE	28.93%
P/E Ratio(TTM)	111.83
EPS(TTM)	79.66
P/B Ratio	27.87
Dividend Yield	0.36%
Industry P/E	39.95
Book Value	319.60
Debt to Equity	0.04
Face Value	2

Understand Fundamentals

Financials

*All values are in Rs. Cr

No Graph Data To Display

Quarterly

Yearly

See Details

About Astrazeneca Pharma India

AstraZeneca Pharma India is a science-led pharmaceutical firm focused on the research, development, and commercialization of prescription medicines for patients globally. The company's purpose is to push the boundaries of science, accelerating the delivery of life-changing treatments that create enduring value for all. Globally, its COVID-19 vaccine is credited with having saved more than six million lives, highlighting its significant impact on public health.;

Parent Organisation	Astrazeneca Pharma India
Managing Director	Mr. Sanjeev Panchal

NSE Symbol

ASTRAZEN

Shareholding Pattern

Sep '24

Dec '24

Mar '25

Jun '25

Sep '25

Promoters
75.00%
Retail And Others
17.00%
Mutual Funds
5.00%
Foreign Institutions
2.74%
Other Domestic Institutions
0.26%

Top Mutual Funds Invested(4)

FUND NAME	AUM(%)
Bandhan Aggressive Hybrid Fund Direct Growth	1.14%
Nippon India Small Cap Fund Direct Growth	0.87%
ICICI Prudential Retirement Fund Hybrid Aggressive Plan Direct Growth	0.83%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth	0.77%

Similar Stocks

COMPANY	MARKET PRICE	P/E Ratio
Abbott India	NA (0.00%)	40.66
GlaxoSmithKline Pharmaceuticals	NA (0.00%)	43.71
Pfizer	NA (0.00%)	27.52
Sanofi Consumer Healthcare India	NA (0.00%)	47.16

ScoutQuest . 2 weeks ago

AstraZeneca Pharma India gets approval for import, sale, and distribution of Datverzo. Datverzo, a 100 mg infusion powder, targets specific breast cancer patients post prior therapies.

Simply Wall Street . 3 weeks ago

AstraZeneca Pharma India shows strong fundamentals with a 25% ROE, outperforming the industry average of 11%. The company retains 61% of profits, driving 16% net income growth over 5 years and paying dividends for six years.

ScoutQuest . 1 month ago

AstraZeneca Pharma India's FY 2020-21 tax addition of Rs. 13.11 cr deemed erroneous. Appeal led to order to delete addition, favorable tax impact estimated at Rs. 3.3 cr.

Livemint . 1 month ago

Indian markets poised for flat open after 6-day gains; investors await US data for Fed rate clarity. Stocks to watch: Blackstone pares Mphasis stake; Elevation Capital sells Paytm shares; AstraZeneca, Sun Pharma pact.

Livesquawk . 1 month ago

AstraZeneca Pharma India partners with Sun Pharma to develop hyperkalaemia therapy. Hyperkalaemia is a condition marked by elevated potassium levels in blood.

BSE . 1 month ago

AstraZeneca Pharma India partners with Sun Pharma for Sodium Zirconium Cyclosilicate distribution in India. Deal includes Rs. 26 crore payment; SZC marketed as Lokelma by AstraZeneca and Gimliand by Sun Pharma.

ScoutQuest . 2 months ago

AstraZeneca Pharma India reports 37% revenue growth in Q2 FY26, PAT doubled YoY. Seven CDSCO approvals in H1 FY25, driven by Oncology, Biopharma, Rare Diseases.

Livesquawk . 2 months ago

AstraZeneca Pharma's Q2 EBITDA surged to 752M rupees, up from 524M YoY. EBITDA margin improved to 13.5%, compared to 12.8% YoY.

BSE . 2 months ago

AstraZeneca Pharma India Ltd will hold a board meeting on Nov 7, 2025, to review unaudited Q2 & half-year results. Trading window is closed for designated persons from Sep 16 to Nov 9, 2025, as per insider trading regulations.

Marketsmojo . 3 months ago

AstraZeneca Pharma India is priced at ₹9,360, up 26.2% YoY despite reduced investor interest. Positive financials and efficient management support a stable outlook despite being costlier than peers.

2025

Nov

Quarterly Result

Release date

Check latest financial

Aug

Quarterly Result

Release date

Check latest financial

18
Jul
Dividend
Ex date
₹32.00
per share

For each share you hold, you will receive ₹32.00

Dividend amount₹32.00 per share

Dividend TypeFinal

Ex Date18 Jul ‘25

Record Date18 Jul ‘25

Announcement date30 May ‘25

30
May
Dividend
Announced
₹32.00
per share

For each share you hold, you will receive ₹32.00

Dividend amount₹32.00 per share

Dividend TypeFinal

Ex Date18 Jul ‘25

Record Date18 Jul ‘25

Announcement date30 May ‘25

May

Annual Result

Release date

Check latest financial

Feb

Quarterly Result

Release date

Check latest financial

2024

Nov

Quarterly Result

Release date

Check latest financial

Aug

Quarterly Result

Release date

Check latest financial

5
Jul
Dividend
Ex date
₹24.00
per share

For each share you hold, you will receive ₹24.00

Dividend amount₹24.00 per share

Dividend TypeFinal

Ex Date5 Jul ‘24

Record Date5 Jul ‘24

Announcement date27 May ‘24

27
May
Dividend
Announced
₹24.00
per share

For each share you hold, you will receive ₹24.00

Dividend amount₹24.00 per share

Dividend TypeFinal

Ex Date5 Jul ‘24

Record Date5 Jul ‘24

Announcement date27 May ‘24

May

Result

Release date

Check latest financial

Events calendar

View upcoming events in other stocks

Home>Stocks>Astrazeneca Pharma India

Vaishnavi Tech Park, South Tower, 3rd FloorSarjapur Main Road, Bellandur, Bengaluru – 560103Karnataka

Download the App

Share Market

Indices

F&O

Mutual Funds

ETFs

Funds By Groww

Calculators

IPO

Miscellaneous

NIFTY Bank Options SBI Options Bajaj Finance Options Axis Bank Options Hindustan Unilever Options NIFTY Bank Futures Finnifty Futures ITC Futures ICICI Bank Futures Biocon Futures Indusind Bank Futures

NIFTY 50 Options HDFC Bank Options Wipro Options DLF Options REC Options Yes Bank Futures Zomato Futures Ashok Leyland Futures HDFC Bank Futures UPL Futures Adani Enterprises Futures

Bse Sensex Options Tata Steel Options NTPC Options Bajaj Auto Options Indusind Bank Options Tata Motors Futures Infosys Futures Asian Paints Futures Lupin Futures Cipla Futures IDFC First Bank Futures

Finnifty Options Infosys Options Asian Paints Options Coal India Options Ashok Leyland Options Tata Steel Futures BSE Sensex Futures Wipro Futures DLF Futures Bajaj Finance Futures Piramal Enterprises Futures

Tata Motors Options ITC Options ICICI Bank Options Adani Enterprises Options NIFTY 50 Futures Coal India Futures Axis Bank Futures Vedanta Futures Reliance Industries Futures Hindustan Copper Futures

MF Screener Debt Mutual Funds Best Multicap Mutual funds Best Contra Mutual funds Best Conservative Mutual funds SBI Contra Fund Nippon India Nifty 500 Momentum 50 Index Fund HDFC Balanced Advantage Fund Quant Mid Cap Fund Bank of India Small Cap Fund Quant Multi Asset Fund Nippon India TATA Bandhan Edelweiss HSBC Union Quantum Shriram

Compare Mutual Funds Best Debt Mutual funds Best Large Cap Mutual funds Best Value Mutual funds Parag Parikh Flexi Cap Fund HDFC Mid Cap Opportunities Fund Motilal Oswal Nifty India Defence Index Fund ICICI Prudential India Opportunities Fund Kotak Small Cap Fund Canara Robeco Bluechip Equity Fund GrowwMF Motilal Oswal Aditya Birla Axis Bank of India Bajaj Finserv Helios ITI Trust

MF Knowledge Centre Best Equity Mutual funds Best Small Cap Mutual funds Best Arbitrage Mutual funds Motilal Oswal Midcap Fund SBI Small Cap Fund HDFC Small Cap Fund Kotak Multicap Fund ICICI Prudential Infrastructure Fund Bandhan Nifty Alpha 50 Index Fund SBI Quant Mirae Asset DSP Baroda BNP Paribas Mahindra Manulife Sundaram Samco Taurus

Mutual Fund Houses Best Hybrid Mutual funds Best ELSS Mutual funds Best Dividend Yield Mutual funds Nippon India Small Cap Fund HDFC Flexi Cap Fund Tata Small Cap Fund Tata Ethical Fund Mirae Asset ELSS Tax Saver Fund Quant Infrastructure Fund HDFC PPFAS UTI Kotak Mahindra Zerodha Invesco Navi PGIM

Mutual Funds Categories Best MidCap Mutual funds Best Sector Mutual funds Best Aggressive Mutual funds Quant Small Cap Fund SBI Magnum Children's Benefit Fund UTI Nifty 50 Index Fund JM Flexicap Fund HSBC Small Cap Fund Franklin India Multi Cap Fund ICICI Prudential LIC Canara Robeco Whiteoak Franklin Templeton NJ JM 360 One

International Silver Midcap Liquid

Debt Index Bank Nifty Nifty IT

Equity Nifty 50 Nifty Metal Nifty Auto

Commodity Nifty Next 50 Healthcare Groww

Gold Sensex Defence

What is IPO?What is Grey Market Premium?

Open IPOs Mainboard IPOs

Upcoming IPOs SME IPOs

Closed IPOs IPO Allotment Status

How to Apply for an IPO

NFO Pricing Trust & Safety Recurring Deposit

Intraday Blog Investor Relations Groww Digest

Corporate Bonds Media & Press Gold Rates Invest in Gold

HUF Demat Account Careers Glossary Sitemap

About Us Help & Support Fixed Deposit

Others:

NSEBSEMCXTerms and ConditionsPolicies and ProceduresRegulatory & Other InfoPrivacy PolicyDisclosureSMART ODRDownload FormsInformation Security PracticesInvestor Charter and GrievanceBug Bounty

Mutual Funds:

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Others

About Groww

Groww is India's largest Stock Broker with more than 1.4 crore active customers where users can find their investment solutions pertaining to mutual funds, stocks, US Stocks, ETFs, IPO, and F&Os, to invest their money without hassles.

Groww objectively evaluates stocks and mutual funds and does not advise or recommend any stocks, mutual funds or portfolios. Investors shall invest at their own discretion, will and consent. Groww, at any time, does not guarantee fixed returns on the capital invested.

Groww helps investors -

· By providing 100% paperless online free Demat and trading account opening

· By providing an objective evaluation of products available on the platform

· By being transparent about fees and charges involved while investing in a product

· By offering decision-making assistance by providing technical analysis with advanced charts, well-designed line & candlestick charts that indicate share price movements, and market indices, along with more details about all registered and listed companies

SECURE TRANSACTIONS ON GROWW

All transactions on Groww are safe and secure. Users can invest through SIP or Lumpsum using Netbanking through all supported banks. It uses BSE Star MF (with Member code 11724) as transaction platform.

TRADE AND INVEST SECURELY WITH GROWW

Stocks, Mutual fund investments, F&Os, etc., are very popular with individual investors because of their numerous benefits. On Groww, an investor can -

- Invest in Nifty 50 (NSE) & Sensex (BSE) listed stocks

- Diversify across multiple stocks and other instruments

- Start SIP with any amount (as low as Rs. 500)

- Switch regular funds to direct funds

- Start automated monthly investments (SIP), and benefit from many more features

All type of mutual funds are available on Groww.

INVESTING IN MUTUAL FUND PORTFOLIOS

Portfolio is collection of mutual funds designed to meet your investment goals. Investing in mutual fund portfolios helps you in diversifying your investments and reduces the risk. Portfolios also help you in assigning an investment goals and make it easy for you to save for and achieve your goals. You can create a portfolio yourself or ask an expert to build it for you.

ATTENTION INVESTORS

1. For Stock Broking Transaction 'Prevent unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day...Issued in the interest of Investors.

2. For Depository Transaction 'Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL/NSDL on the same day...Issued in the interest of investors.

3. KYC is a one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

4. If you are subscribing to an IPO, there is no need to issue a cheque. Please write the Bank account number and sign the IPO application form to authorize your bank to make payment in case of allotment. In case of non allotment the funds will remain in your bank account.

· Investors should be cautious on unsolicited emails and SMS advising to buy, sell or hold securities and trade only on the basis of informed decision. Investors are advised to invest after conducting appropriate analysis of respective companies and not to blindly follow unfounded rumours, tips etc. Further, you are also requested to share your knowledge or evidence of systemic wrongdoing, potential frauds or unethical behaviour through the anonymous portal facility provided on BSE & NSE website.

· Awareness regarding guidelines on Margin collection

1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

2. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

3. Pay 20% upfront margin of the transaction value to trade in cash market segment.

4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.

Issued in the interest of Investors

DISCLAIMER

Groww Invest Tech Pvt. Ltd. (Formerly known as Nextbillion Technology Pvt. Ltd) (CIN: U65100KA2016PTC092879) is a member of NSE & BSE & MCX with SEBI Registration no: INZ000301838, Depository Participant of CDSL Depository with SEBI Registration no: IN-DP-417-2019 and Mutual Fund distributor with AMFI Registration No: ARN-111686. Registered office and Correspondence office - Vaishnavi Tech Park, South Tower, 3rd floor, Sarjapur Main Road, Bellandur, Bengaluru – 560103, Karnataka. For any grievances related to Stock Broking/DP, please write to [email protected] , please ensure you carefully read the Risk Disclosure Document as prescribed by SEBI.

Procedure to file a complaint on SEBI SCORES: Register on the SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances.

Groww Invest Tech Pvt. Ltd. (Formerly known as Nextbillion Technology Pvt. Ltd) makes no warranties or representations, express or implied, on products offered through the platform. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Unless otherwise specified, all returns, expense ratio, NAV, etc are historical and for illustrative purposes only. Future will vary greatly and depends on personal and market circumstances. The information provided by our blog is educational only and is not investment or tax advice.

Investment in Securities Market are subject to market risks, read all the related documents carefully before investing

Mutual fund investments are subject to market risks. Please read all scheme related documents carefully before investing. Past performance of the schemes is neither an indicator nor a guarantee of future performance.

India's largest Stock Broker by active users on NSE as of June 30, 2025. Refer: NSE's Arbitration status

Terms and conditions of the website/app are applicable. Privacy policy of the website is applicable.

Astrazeneca Pharma India

Performance

Fundamentals

Financials

About Astrazeneca Pharma India

Shareholding Pattern

Top Mutual Funds Invested(4)

Similar Stocks

18JulDividendEx date₹32.00per share

30MayDividendAnnounced₹32.00per share

5JulDividendEx date₹24.00per share

27MayDividendAnnounced₹24.00per share

About Groww

18
Jul
Dividend
Ex date
₹32.00
per share

30
May
Dividend
Announced
₹32.00
per share

5
Jul
Dividend
Ex date
₹24.00
per share

27
May
Dividend
Announced
₹24.00
per share